224 related articles for article (PubMed ID: 11881494)
1. [Humoral response to the injection of acellular Pertussis vaccine].
Zakharova NS; Remova TN; Britsina MV; Shmeleva EI; Mertsalova NU; Zaĭtsev EM; Ozeretskovskaia MN; Bazhanova IG; Ermolova EV
Zh Mikrobiol Epidemiol Immunobiol; 2001; (6):40-4. PubMed ID: 11881494
[TBL] [Abstract][Full Text] [Related]
2. [Acellular pertussis vaccine].
Zakharova NS; Britsina MV; Mertsalova NU; Bazhanova IG; Ozeretskovskaia MN; Zaĭtsev EM; Poddubikov AV; Semenov BF
Zh Mikrobiol Epidemiol Immunobiol; 2008; (1):35-41. PubMed ID: 18368750
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
[TBL] [Abstract][Full Text] [Related]
4. Serum antibody response to B. pertussis Tn5 mutants, purified PT and FHA in two different mouse strains and passive protection in the murine intranasal infection model.
Olander RM; Muotiala A; Karvonen M; Kuronen T; Runeberg-Nyman K
Microb Pathog; 1990 Jan; 8(1):37-45. PubMed ID: 2159104
[TBL] [Abstract][Full Text] [Related]
5. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.
Annunziato PW; Rothstein EP; Bernstein HH; Blatter MM; Reisinger KS; Pichichero ME
Arch Pediatr Adolesc Med; 1994 May; 148(5):503-7. PubMed ID: 8180641
[TBL] [Abstract][Full Text] [Related]
8. Anti-pertussis toxin IgG and anti-filamentous hemagglutinin IgG production in children immunized with pertussis acellular vaccine and comparison of these titers with the sera of pertussis convalescent children.
Sato Y; Sato H
Dev Biol Stand; 1985; 61():367-72. PubMed ID: 3835079
[TBL] [Abstract][Full Text] [Related]
9. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pertussis vaccines consisted of antigens detoxified with tea-leaf catechins.
Watanabe M; Funaishi K; Takeo T; Endoh M
Vaccine; 2000 Dec; 19(9-10):1204-10. PubMed ID: 11137258
[TBL] [Abstract][Full Text] [Related]
11. Acellular and whole cell pertussis vaccines protect against the lethal effects of intracerebral challenge by two different T-cell dependent humoral routes.
Wiertz EJ; Walvoort HC; Van Loveren H; Van Straaten-Van De Kappelle I; Van Der Gun JW; Kreeftenberg JG
Biologicals; 1990 Jul; 18(3):173-80. PubMed ID: 2257130
[TBL] [Abstract][Full Text] [Related]
12. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines.
Meade BD; Lynn F; Reed GF; Mink CM; Romani TA; Deforest A; Deloria MA
Pediatrics; 1995 Sep; 96(3 Pt 2):595-600. PubMed ID: 7659484
[TBL] [Abstract][Full Text] [Related]
13. Antibody Specificity Following a Recent
Raeven RHM; van der Maas L; Pennings JLA; Fuursted K; Jørgensen CS; van Riet E; Metz B; Kersten GFA; Dalby T
Front Immunol; 2019; 10():1364. PubMed ID: 31275314
[No Abstract] [Full Text] [Related]
14. Determination of circulating antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal.
Relyveld E; Oato NH; Guérin N; Coursaget P; Huet M; Gupta RK
Vaccine; 1991 Nov; 9(11):843-50. PubMed ID: 1759508
[TBL] [Abstract][Full Text] [Related]
15. Restricted antibody response to Bordetella pertussis filamentous hemagglutinin induced by whole-cell and acellular pertussis vaccines.
Asgarian-Omran H; Golara M; Abdolmaleki S; Navabi SS; Alipour H; Khoshnoodi J; Hemmati A; Zarei S; Jeddi-Tehrani M; Shokri F
Infect Dis (Lond); 2016 Feb; 48(2):127-32. PubMed ID: 26439274
[TBL] [Abstract][Full Text] [Related]
16. Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
Blanchard Rohner G; Chatzis O; Chinwangso P; Rohr M; Grillet S; Salomon C; Lemaître B; Boonrak P; Lawpoolsri S; Clutterbuck E; Poredi IK; Wijagkanalan W; Spiegel J; Pham HT; Viviani S; Siegrist CA
Clin Infect Dis; 2019 Mar; 68(7):1213-1222. PubMed ID: 30759183
[TBL] [Abstract][Full Text] [Related]
17. [Immunobiological properties of Bordetella pertussis lipopolysaccharide in the acellular pertussis vaccine].
Zaĭtsev EM; Poddubikov AV; Britsina MV; Mertsalova NU; Ozeretskovskaia MN; Bazhanova IG; Plekhanova NG
Zh Mikrobiol Epidemiol Immunobiol; 2014; (1):20-4. PubMed ID: 24738289
[TBL] [Abstract][Full Text] [Related]
18. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.
Giuliano M; Mastrantonio P; Giammanco A; Piscitelli A; Salmaso S; Wassilak SG
J Pediatr; 1998 Jun; 132(6):983-8. PubMed ID: 9627590
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of chemically cross-linked antigens for acellular pertussis vaccine.
Watanabe M; Nagai M; Funaishi K; Endoh M
Vaccine; 2000 Dec; 19(9-10):1199-203. PubMed ID: 11137257
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
